PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.

PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.

In tauopathies, a neural microtubule-associated protein tau (MAPT) is abnormally aggregated and forms neurofibrillary tangle. Therefore, inhibition of the tau aggregation is one of the key approaches for the treatment of these diseases. Here, we have identified a novel tau aggregation inhibitor, PE8...

Full description

Bibliographic Details
Main Authors: Michiaki Okuda, Ichiro Hijikuro, Yuki Fujita, Xiaofeng Wu, Shinichi Nakayama, Yoko Sakata, Yuji Noguchi, Makoto Ogo, Shigeru Akasofu, Yoshimasa Ito, Yoshiyuki Soeda, Nobuhiko Tsuchiya, Naoki Tanaka, Takashi Takahashi, Hachiro Sugimoto
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4319983?pdf=render

Similar Items

Similar Items